VASH1 expression was positively correlated with drug sensitivity for FK866, Navitoclax, SB52334, Z-LLNle-CHO, Vorinostat, Cetuximab, Afatinib, CGP-60474, CGP-082996, GSK1070916, JW-7-52–1, CX-5461, XAV939, A-770041, and AKT inhibitor VIII (all r > 0.10 and P < 0.01), and negatively associated with drug sensitivity for TW37, AC220, Dasatinib, CAY10603, Camptothecin, ZG-10, Rapamycin, 17-AAG, AZD6482, Genentech Cpd 10, BX-912, Talazoparib, OSI-027, Paclitaxel, and Gefitinib (all r < −0.10 and P < 0.01)in the Genomics of Drug Sensitivity to Cancer (GDSC) database (Figure 10(a) and Table S1). This evidence concerns the gene AKT1 and cancer.